4.7 Article

Tanshinone I exerts cardiovascular protective effects in vivo and in vitro through inhibiting necroptosis via Akt/Nrf2 signaling pathway

Journal

CHINESE MEDICINE
Volume 16, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13020-021-00458-7

Keywords

Tanshinone I; Oxidative stress; Necroptosis; Myocardial ischemia reperfusion; RIP1/RIP3/MLKL; Akt/Nrf2

Funding

  1. Guangxi Science and Technology Base and Talent Special Project [2018AD19034]
  2. Project of Guangxi Innovation-driven Development [2019AA17002]
  3. Guangxi Key Research and Development Plan [2020AB39014]
  4. National Natural Science Foundation of China (NSFC, China) [81803807, 81860711]
  5. Guangxi Natural Science Foundation [2018JJB140265, 2018JJB140263]
  6. Qihuang High-level Talent Team Cultivation Project of Guangxi University of Chinese Medicine [2021002]
  7. Project of Guangxi Overseas 100 persons plan High-level Expert
  8. Guangxi Higher Education institutions Comprehensive Improvement Project 2021: Guangxi Collabrative Innovation Center for Scientific Achievements Transformation and Application on Traditional Chinese Medicine [0502101003]

Ask authors/readers for more resources

The study showed that Tanshinone I exerted cardiovascular protective effects both in vitro and in vivo by inhibiting RIP1/RIP3/MLKL and activating Akt/Nrf2 signaling pathways. It can alleviate oxidative stress, promote the expression of antioxidant-related proteins, and protect against myocardial ischemia-reperfusion injury.
Background: Tanshinone I (TI) is a primary component of Salvia miltiorrhiza Bunge (Danshen), which confers a favorable role in a variety of pharmacological activities including cardiovascular protection. However, the exact mechanism of the cardiovascular protection activity of TI remains to be illustrated. In this study, the cardiovascular protective effect and its mechanism of TI were investigated. Methods: In this study, tert-butyl hydroperoxide (t-BHP)-stimulated H9c2 cells model was employed to investigate the protective effect in vitro. The cell viability was determined by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay and lactate dehydrogenase (LDH) kit. The reactive-oxygen-species (ROS) level and mitochondrial membrane potential (MMP) were investigated by the flow cytometry and JC-1 assay, respectively. While in vivo experiment, the cardiovascular protective effect of TI was determined by using myocardial ischemia-reperfusion (MI/R) model including hematoxylin-eosin (H&E) staining assay and determination of superoxide dismutase (SOD) and malondialdehyde (MDA). Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) release were detected by Enzyme-linked immunosorbent assay (ELISA). Receptor interacting protein kinase 1 (RIP1), receptor interacting protein kinase 3 (RIP3), receptor interacting protein kinase 3 (MLKL), protein kinase B (Akt), Nuclear factor erythroid 2 related factor 2 (Nrf2), Heme oxygenase-1 (HO-1) and NAD(P)H: quinone oxidoreductase-1 (NQO-1) were determined by western blotting. Results: Our data demonstrated that TI pretreatment attenuated t-BHP and MI/R injury-induced necroptosis by inhibiting the expression of p-RIP1, p-RIP3, and p-MLKL. TI activated the Akt/Nrf2 pathway to promote the expression of antioxidant-related proteins such as phosphorylation of Akt, nuclear factor erythroid 2 related factor 2 (Nrf2), quinone oxidoreductase-1 (NQO-1) and heme oxygenase-1 (HO-1) expression in t-BHP-stimulated H9c2 cells. TI relieved oxidative stress by mitigating ROS generation and reversing MMP loss. In vivo experiment, TI made electrocardiograph (ECG) recovery better and lessened the degree of myocardial tissue damage. The counts of white blood cell (WBC), neutrophil (Neu), lymphocyte (Lym), and the release of TNF-alpha and IL-6 were reversed by TI treatment. SOD level was increased, while MDA level was decreased by TI treatment. Conclusion: Collectively, our findings indicated that TI exerted cardiovascular protective activities in vitro and in vivo through suppressing RIP1/RIP3/MLKL and activating Akt/Nrf2 signaling pathways, which could be developed into a cardiovascular protective agent.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available